Target: Amyloid Beta.
Specificity: Detects human Amyloid Beta. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Aducanumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RUO Aducanumab is a human monoclonal antibody that selectively targets aggregated amyloid beta. In a transgenic mouse model of Alzheimer’s disease, aducanumab is shown to enter the brain, bind parenchymal amyloid beta, and reduce soluble and insoluble amyloid beta in a dose-dependent manner.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
